After a string of failures, Winston-Salem, North Carolina-based Targacept and its neuronal nicotinic receptor (NNR) therapeutics will be replaced by engineered human proteases for hemophilia and complement-mediated disorders in a reverse merger with privately-held Catalyst Biosciences in South San Francisco.
Publicly-held Targacept will be known as Catalyst and its stock market ticker symbol will change from TRGT to CBIO. The...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?